Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesMagnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopyAssessing neurotoxicity from the low-dose radiation component of radiosurgery using magnetic resonance spectroscopy.Linking structural, metabolic and functional changes in multiple sclerosis.Neuroimaging in leukodystrophies.Proton magnetic resonance spectroscopy: an emerging technology in pediatric neurology research.Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response.Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrationsDetermination of multiple sclerosis plaque size with diffusion-tensor MR Imaging: comparison study with healthy volunteers.Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions.1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study.The application of NMR-based metabonomics in neurological disorders.Metabolite 1H relaxation in normal and hyponatremic brain.Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force.Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.Remyelinating strategies in multiple sclerosis.Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.MS clinical trial design for the future.Immune and non-immune actions of interferon-beta-Ib on primary human neural cells.Pattern recognition approaches in biomedical and clinical magnetic resonance spectroscopy: a review.Novel pathologic findings in patients with Pelizaeus-Merzbacher disease.The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve.Chronic intermittent but not constant hypoxia decreases NAA/Cr ratios in neonatal mouse hippocampus and thalamus.Randomized trial of erhuangfang for relapsing multiple sclerosis.Axonal pathology in multiple sclerosis. A historical note.T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation.Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease.Immunopathology of secondary-progressive multiple sclerosis.
P2860
Q22241472-C057489B-CA54-42FC-AD21-65A86B160088Q24800569-8181F26F-67E0-45C6-AD58-6E720C6D7969Q30477377-C4685E2B-3186-428E-9179-44F465564A55Q30654880-8D31B1BE-AE0F-46DB-9E4F-B827557E0896Q30978716-625868C8-E32A-43D9-8E20-6B9A2880C9CFQ32053186-61467862-A095-4E3D-BC3A-205E6503FDF1Q34590280-97B7F3E0-28D4-4A4F-8B44-1164086A0AC5Q35456727-86E9F3B3-832D-4300-864B-072EF50114A4Q35652686-BA6A8594-6D9E-42CA-985E-5181118AADEAQ35745974-357070E9-4A3E-4DCC-BBD4-30DA46CAFAD4Q36317738-C11D2721-2CA3-467F-955C-F46841435126Q36525175-E4DC4CEC-6DAB-400C-95D7-DA9C5C88960FQ36809318-AE0612B6-727C-4AA9-ACB8-115013163389Q36814514-5DAD3454-5B29-4223-8C7C-040CB1F8DFC6Q36887909-2C4DB077-8B7C-4C3A-BE74-9B7C118C7E80Q36993507-66B84B8D-5F6B-468C-AE9A-24ECF6122F3DQ37685038-8EACC88A-6D70-42E7-B56B-EFCBFBF324E7Q38083041-FDA83D8C-6C99-4C80-8454-48E6664F3891Q38111421-6893D6A0-7D19-43F7-9D36-746904C9FFCAQ38261543-0FF7023C-1C36-4274-948F-134008E8B895Q38444650-275AE0A3-6972-4B2E-83E6-A14C5CB0855AQ40934002-6B2C00CB-5B96-43AB-BF7F-369288EC899DQ41351934-85D3C97A-8893-4580-9C4B-040FD02B4D7CQ41668595-1297EE4D-3288-4928-A5F2-B1F1E66BC467Q41906878-CA5EB45B-E3DA-422B-AEDB-43A5341852FAQ42443517-0E55AD9F-1891-43A3-90C9-FA9A1A967AB4Q43849057-8D559F04-B7F8-49D5-85BB-DE6C92D147EAQ46661314-EE49B16A-FE84-4454-B016-6532EA81FBA3Q47438584-B07F92AF-B8A7-4A97-B427-D03E2A6607A2Q48093198-ECAD3F65-A081-46CF-A9E4-743E4E3AB18FQ48336758-7A1BE7D1-FC48-44C1-8B80-1D61089266C9Q48353766-5852F09F-E60B-4580-8028-6469AFDF2BBBQ48713004-3FB40E2D-56E3-43B1-A2E2-09001D7A9DB1
P2860
Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Use of proton magnetic resonan ...... ression in multiple sclerosis.
@en
Use of proton magnetic resonan ...... ression in multiple sclerosis.
@nl
type
label
Use of proton magnetic resonan ...... ression in multiple sclerosis.
@en
Use of proton magnetic resonan ...... ression in multiple sclerosis.
@nl
prefLabel
Use of proton magnetic resonan ...... ression in multiple sclerosis.
@en
Use of proton magnetic resonan ...... ression in multiple sclerosis.
@nl
P2093
P2860
P356
P1433
P1476
Use of proton magnetic resonan ...... gression in multiple sclerosis
@en
P2093
P2860
P356
10.1002/ANA.410360115
P577
1994-07-01T00:00:00Z